Long-term stability of ready-to-use 1-mg/mL midazolam solution.


Journal

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
ISSN: 1535-2900
Titre abrégé: Am J Health Syst Pharm
Pays: England
ID NLM: 9503023

Informations de publication

Date de publication:
27 Apr 2020
Historique:
pubmed: 18 4 2020
medline: 12 1 2021
entrez: 18 4 2020
Statut: ppublish

Résumé

Midazolam is a benzodiazepine derivative commonly used in intensive care units to control sedation. Its use requires dilution of a 5-mg/mL commercial solution to a target concentration of 1 mg/mL. A study was conducted to evaluate the stability of diluted ready-to-use 1-mg/mL midazolam solutions over 365 days when stored in cyclic olefin copolymer vials or polypropylene syringes. A specific stability-indicating high-performance liquid chromatography coupled with UV detection method was developed for midazolam hydrochloride and validated for selectivity, linearity, sensitivity, precision, and accuracy. Three storage conditions were tested: -20°C ± 5°C, 5°C ± 3°C, and 25°C ± 2°C at 60% ± 5% relative humidity. Half of the vials were stored upside down to test for the absence of interaction between midazolam and the stopper. Particle contamination, sterility, and pH were assessed. The limit of stability was set at 90% of the initial concentration. After 1 year's storage at -20°C and 5°C, concentrations remained superior to 90% under all storage conditions. At 25°C, stability was maintained up to day 90 in syringes (mean [SD], 92.71% [1.43%]) and to day 180 in upright and upside-down vials (92.12% [0.15%] and 91.57% [0.15%], respectively). No degradation products were apparent, no variations in pH values were detected, and containers retained their sterility and conformity with regard to any specific contamination during the study. The evaluated 1-mg/mL midazolam solution was stable over a 1-year period when stored at a refrigerated (5°C) or frozen (-20°C) temperature in both vials and syringes; with storage at 25°C, the stability duration was lower. The preparation of ready-to-use midazolam solutions by a hospital pharmacy is compatible with clinical practice and could help to decrease risks inherent in dilution in care units.

Identifiants

pubmed: 32300788
pii: 5821086
doi: 10.1093/ajhp/zxaa040
doi:

Substances chimiques

Hypnotics and Sedatives 0
Polypropylenes 0
Midazolam R60L0SM5BC

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

681-689

Informations de copyright

© American Society of Health-System Pharmacists 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Sixtine Gilliot (S)

Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA), Centre Hospitalier Universitaire de Lille, Lille, France.

Morgane Masse (M)

Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA), Centre Hospitalier Universitaire de Lille, Lille, France.

Frédéric Feutry (F)

Service of Pharmacy, Centre Oscar Lambret, Lille, France.

Christine Barthélémy (C)

Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA), Centre Hospitalier Universitaire de Lille, Lille, France.

Bertrand Décaudin (B)

Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA), Centre Hospitalier Universitaire de Lille, Lille, France.

Stéphanie Genay (S)

Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA), Centre Hospitalier Universitaire de Lille, Lille, France.

Pascal Odou (P)

Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA), Centre Hospitalier Universitaire de Lille, Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH